No siempre es un error evidente. A veces no hay una operación fallida ni un diagnóstico claramente equivocado. En muchos casos, el problema es más sutil: una prueba que llega tarde, una decisión que se retrasa o una señal clínica que pasa desaperci …
James Cleary will step down from the post on June 30, but stay on as an adviser to the company through the end of the year. He’s the second finance chief of a drug distributor to announce their retirement this month.
The Federal Trade Commission said the transaction had threatened to raise prices and stifle innovation for cataract laser eye surgery systems.
Alcon abandons effort to purchase LENSAR after FTC scrutiny Read More »
Researchers warn that Microsoft Intune may have been weaponized to wipe critical devices.
Stryker attack raises concerns about role of device management tool Read More »
Although FDA Commissioner Marty Makary promised “an exciting treatment” for autism, what the agency delivered was a label expansion for leucovorin to treat the ultrarare cerebral folate deficiency. The regulatory process, which relied on a literature review rather than new evidence, stands in contrast to recent rare disease rejections in which the FDA cited a
What the Leucovorin Approval Signals—or Doesn’t—About the FDA’s Rare Disease Stance Read More »
In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and well-controlled studies. The FDA previously turned the candidate away in November 2023 and April 2025.
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting Read More »
The ruling, related to a lawsuit from several major medical organizations, said that HHS ignored established protocols when altering the childhood immunization schedule and overhauling a key CDC panel.
Federal court blocks RFK Jr.’s moves to upend US vaccine policy Read More »
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test Read More »
La enfermedad celíaca es un trastorno autoinmune que se desencadena cuando una persona con predisposición genética consume gluten. Sin embargo, la genética por sí sola no explica por qué algunas personas desarrollan la enfermedad y otras no. En los úl …
Enfermedad celíaca propiciada por infecciones virales Read More »
La enfermedad de Alzheimer, la principal causa de demencia en las poblaciones envejecidas de todo el mundo, se caracteriza por una cascada patológica distintiva: las placas de beta-amiloide se acumulan en el cerebro, desencadenando cambios perjudiciales en las proteínas tau, lo que en …
